{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/6882eccb2a38d6f5cb7e6a4d?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs","description":"<p>Sarepta has temporarily paused shipments of Elevidys, its FDA-approved treatment for Duchenne muscular dystrophy. In this episode of <em>GEN</em>'s <em>Touching Base</em>, we discuss the company’s response to the tragedies associated with its DMD therapy as well as with a new therapy for limb-girdle muscular dystrophy. Also in this episode, big updates from AstraZeneca including a $50 billion investment in U.S. manufacturing and R&amp;D, a heartwarming story about preventing mitochondrial disease involving eight babies from the U.K., and from the lab of Nobel Prize winner David Baker, PhD, AI that designs drugs for previously “undruggable” proteins.</p><p><br></p><p>Join <em>GEN</em> editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.</p><p><br></p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>:</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/genome-editing/about-face-sarepta-to-pause-elevidys-shipments-temporarily/\" rel=\"noopener noreferrer\" target=\"_blank\">About Face: Sarepta to Pause Elevidys Shipments Temporarily</a></p><p>By Alex Philippidis, <em>GEN Edge,</em> July 21, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/genome-editing/stockwatch-sarepta-shares-nosedive-after-lgmd-gene-therapy-patient-dies/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies</a></p><p>By Alex Philippidis, <em>GEN Edge,</em> July 20, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/gen-edge/sarepta-axes-500-36-of-workforce-in-restructuring-after-dmd-patient-deaths/\" rel=\"noopener noreferrer\" target=\"_blank\">Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths</a></p><p>By Alex Philippidis, <em>GEN Edge,</em> July 16, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/astrazeneca-commits-50b-more-to-u-s-manufacturing-rd-projects/\" rel=\"noopener noreferrer\" target=\"_blank\">AstraZeneca Commits $50B More to U.S. Manufacturing, R&amp;D Projects</a></p><p>By Alex Philippidis, <em>GEN Edge,</em> July 22, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/bioprocessing/astrazenecas-new-300m-plant-provides-total-control-of-cell-therapy-production/\" rel=\"noopener noreferrer\" target=\"_blank\">AstraZeneca’s New $300M Plant Provides Control of Cell Therapy Production</a></p><p>By Gareth John Macdonald, <em>GEN,</em> May 14, 2025</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/multimedia/beyond-baby-kj-next-steps-in-manufacturing-genome-editing-cures/\" rel=\"noopener noreferrer\" target=\"_blank\">Beyond Baby KJ: Next Steps in Manufacturing Genome Editing Cures</a></p><p>GEN Live, July 30, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/translational-medicine/mitochondrial-disease-milestone-eight-babies-born-free-of-disease-via-pronuclear-transfer/\" rel=\"noopener noreferrer\" target=\"_blank\">Mitochondrial Disease Milestone: Eight Babies Born Free of Disease via Pronuclear Transfer</a></p><p>By Julianna LeMieux, PhD <em>GEN,</em> July 16, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/artificial-intelligence/undruggable-no-more-ai-hits-disordered-proteins-unlocks-therapy-targets/\" rel=\"noopener noreferrer\" target=\"_blank\">Undruggable No More: AI Hits Disordered Proteins, Unlocks Therapy Targets</a></p><p>By Fay Lin, PhD <em>GEN,</em> July 18, 2025</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}